COVID-19 neutralizing antibodies predict disease severity and survival.

Autor: Garcia-Beltran WF; Department of Pathology, Massachusetts General Hospital, Boston, MA., Lam EC; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA., Astudillo MG; Department of Pathology, Massachusetts General Hospital, Boston, MA., Yang D; Department of Pathology, Massachusetts General Hospital, Boston, MA., Miller TE; Department of Pathology, Massachusetts General Hospital, Boston, MA., Feldman J; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA., Hauser BM; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA., Caradonna TM; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA., Clayton KL; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA., Nitido AD; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA., Murali MR; Department of Pathology, Massachusetts General Hospital, Boston, MA.; Department of Medicine, Massachusetts General, Hospital, Boston, MA., Alter G; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA., Charles RC; Infectious Disease Unit, Massachusetts General Hospital, Boston, MA., Dighe A; Department of Pathology, Massachusetts General Hospital, Boston, MA., Branda JA; Department of Pathology, Massachusetts General Hospital, Boston, MA., Lennerz JK; Department of Pathology, Massachusetts General Hospital, Boston, MA., Lingwood D; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA., Schmidt AG; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA., Iafrate AJ; Department of Pathology, Massachusetts General Hospital, Boston, MA., Balazs AB; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA.
Jazyk: angličtina
Zdroj: MedRxiv : the preprint server for health sciences [medRxiv] 2020 Oct 20. Date of Electronic Publication: 2020 Oct 20.
DOI: 10.1101/2020.10.15.20213512
Abstrakt: COVID-19 exhibits variable symptom severity ranging from asymptomatic to life-threatening, yet the relationship between severity and the humoral immune response is poorly understood. We examined antibody responses in 113 COVID-19 patients and found that severe cases resulting in intubation or death exhibited increased inflammatory markers, lymphopenia, and high anti-RBD antibody levels. While anti-RBD IgG levels generally correlated with neutralization titer, quantitation of neutralization potency revealed that high potency was a predictor of survival. In addition to neutralization of wild-type SARS-CoV-2, patient sera were also able to neutralize the recently emerged SARS-CoV-2 mutant D614G, suggesting protection from reinfection by this strain. However, SARS-CoV-2 sera was unable to cross-neutralize a highly-homologous pre-emergent bat coronavirus, WIV1-CoV, that has not yet crossed the species barrier. These results highlight the importance of neutralizing humoral immunity on disease progression and the need to develop broadly protective interventions to prevent future coronavirus pandemics.
Databáze: MEDLINE